Jane Street Group, LLC Cabaletta Bio, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 157,702 shares of CABA stock, worth $361,137. This represents 0.0% of its overall portfolio holdings.

Number of Shares

157,702

Previous 296,615 46.83%

Holding current value

$361,137

Previous $2.22 Million 66.46%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.94 - $8.24 $547,317 - $1.14 Million	-138,913 Reduced 46.83%	157,702 $744,000
Q2 2024 Aug 14, 2024	BUY	$7.22 - $18.82 $1.78 Million - $4.63 Million	245,896 Added 484.82%	296,615 $2.22 Million
Q1 2024 May 15, 2024	SELL	$16.79 - $25.38 $632,815 - $956,572	-37,690 Reduced 42.63%	50,719 $865,000
Q4 2023 Feb 14, 2024	BUY	$12.21 - $23.36 $1.08 Million - $2.07 Million	88,409 New	88,409 $2.01 Million
Q1 2023 May 15, 2023	BUY	$7.08 - $12.62 $451,399 - $804,613	63,757 Added 159.26%	103,791 $858,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $9.3 $27,803 - $404,019	-43,443 Reduced 52.04%	40,034 $370,000
Q3 2022 Nov 14, 2022	BUY	$0.63 - $2.05 $45,560 - $148,253	72,319 Added 648.14%	83,477 $54,000
Q2 2022 Aug 16, 2022	BUY	$0.99 - $2.11 $11,046 - $23,543	11,158 New	11,158 $12,000
Q3 2021 Nov 16, 2021	SELL	$7.0 - $12.5 $114,562 - $204,575	-16,366 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.2 - $11.73 $1,612 - $2,627	224 Added 1.39%	16,366 $141,000
Q1 2021 May 18, 2021	BUY	$10.39 - $14.53 $167,715 - $234,543	16,142 New	16,142 $179,000

Others Institutions Holding CABA

# of Institutions

126

Shares Held

47.9M

Call Options Held

202K

Put Options Held

110K

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Cabaletta Bio, Inc. Transaction History